These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30587959)

  • 1. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
    Ohar J; Tosiello R; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of background long-acting beta
    Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose selection for glycopyrrolate/eFlow
    Donohue JF; Goodin T; Tosiello R; Wheeler A
    Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
    Kerwin EM; Murray L; Niu X; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
    Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
    Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
    Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
    Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
    Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
    Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
    Hanania NA; Yohannes AM; Ozol-Godfrey A; Tocco M; Goodin T; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():865-875. PubMed ID: 33833507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
    Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
    Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
    Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
    Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.